NASDAQ
135.07USD
0.00 (0.00%)
We have scored 25 news catalysts on Apogee Therapeutics, Inc. (APGE) over the past 12 months. The biggest single-day move next to one of them came Jun 22, 2026, when APGE closed +46.7%: “Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer”. Coverage across the window leans positive (average ticker sentiment +0.57). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
8.4B
P/E
—
EPS
—
Beta
0.34
52W range
35.39-135.09
Day range
135.07–135.07
Open
135.07
Prev close
135.07
Volume
0
Avg volume
2.2M
Dividend
0.00
IPO
2023-07-14
Analysts publish price targets on APGE, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
11 analyst price targets from $81 to $135
as of 2026-09-24
The market is within 0% of the median target — broadly agreeing with the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Apogee Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for APGE: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
The price sits at the very top of the published model range, fully matching the $135 median and rejecting all bear cases, which means the market has entirely accepted the announced acquisition at $135.11 per share.
What the disagreement turns on
Whether the AbbVie acquisition will close at the agreed $135.11 per share, a question that cannot be settled by the consumer attention or unit volume data available here.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
